SR One News

BY CATEGORY: ALL / NOTABLE / CLINICAL IMPACT / NEW INVESTMENTS / FINANCING AND PARTNERSHIPS / PEOPLE

BY YEAR: 2023 / 2022 / 2021 / 2020

Ancora Biotech raises $60M in Series A

Frances Benson 6/9/22 Frances Benson 6/9/22

Ancora Biotech raises $60M in Series A

Read More

Mineralys Therapeutics raises $118M in Series B

Frances Benson 6/8/22 Frances Benson 6/8/22

Mineralys Therapeutics raises $118M in Series B

Read More

Frances Benson 6/5/22 Frances Benson 6/5/22

eFFECTOR Therapeutics reports positive interim results in zotatifin (EFT226) Ph1/2 clinical trial

Read More

Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial

Frances Benson 6/3/22 Frances Benson 6/3/22

Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial

Read More

Turning Point Therapeutics to be acquired by Bristol Myers Squibb for $4.1B

Frances Benson 6/3/22 Frances Benson 6/3/22

Turning Point Therapeutics to be acquired by Bristol Myers Squibb for $4.1B

Read More

Odyssey Therapeutics appoints Darryl Patrick as Executive Vice President of Non-Clinical Development

Frances Benson 5/24/22 Frances Benson 5/24/22

Odyssey Therapeutics appoints Darryl Patrick as Executive Vice President of Non-Clinical Development

Read More

Arcellx appoints Michelle Gilson as CFO

Frances Benson 5/23/22 Frances Benson 5/23/22

Arcellx appoints Michelle Gilson as CFO

Read More

Odyssey Therapeutics appoints Jeffrey M. Leiden as Board Chair

Frances Benson 5/19/22 Frances Benson 5/19/22

Odyssey Therapeutics appoints Jeffrey M. Leiden as Board Chair

Read More

Arcellx appoints Olivia Ware to Board of Directors

Frances Benson 5/16/22 Frances Benson 5/16/22

Arcellx appoints Olivia Ware to Board of Directors

Read More

CRISPR Therapeutics appoints Phuong Khanh Morrow as CMO

Frances Benson 5/16/22 Frances Benson 5/16/22

CRISPR Therapeutics appoints Phuong Khanh Morrow as CMO

Read More

Arcellx announces dosing of first patient in its Ph1 clinical trial evaluating ACLX- 001, the first therapeutic in the dosable and controllable ARC- SparX Platform

Frances Benson 5/10/22 Frances Benson 5/10/22

Arcellx announces dosing of first patient in its Ph1 clinical trial evaluating ACLX- 001, the first therapeutic in the dosable and controllable ARC- SparX Platform

Read More

Nkarta Therapeutics raises $230M in follow-on financing

Frances Benson 4/28/22 Frances Benson 4/28/22

Nkarta Therapeutics raises $230M in follow-on financing

Read More

Nkarta Therapeutics announces positive preliminary dose finding data for two lead engineered natural killer cell programs

Frances Benson 4/25/22 Frances Benson 4/25/22

Nkarta Therapeutics announces positive preliminary dose finding data for two lead engineered natural killer cell programs

Read More

BioTheryX appoints Jeff Caravella as CFO

Frances Benson 4/25/22 Frances Benson 4/25/22

BioTheryX appoints Jeff Caravella as CFO

Read More

CRISPR Therapeutics appoints Maria Fardis to Board of Directors

Frances Benson 4/12/22 Frances Benson 4/12/22

CRISPR Therapeutics appoints Maria Fardis to Board of Directors

Read More

ARS Pharmaceuticals appoints Eric Karas as Chief Commercial Officer and Kathleen Scott as CFO

Frances Benson 4/5/22 Frances Benson 4/5/22

ARS Pharmaceuticals appoints Eric Karas as Chief Commercial Officer and Kathleen Scott as CFO

Read More

Nimbus Therapeutics presents clinical data from Ph1 study of oral allosteric TYK2 inhibitor at AAD Annual Meeting

Frances Benson 3/25/22 Frances Benson 3/25/22

Nimbus Therapeutics presents clinical data from Ph1 study of oral allosteric TYK2 inhibitor at AAD Annual Meeting

Read More

MiroBio continues expansion of executive leadership team

Frances Benson 3/8/22 Frances Benson 3/8/22

MiroBio continues expansion of executive leadership team

Read More

BioTheryX appoints Nancy Miller- Rich as Board Chair

Frances Benson 2/23/22 Frances Benson 2/23/22

BioTheryX appoints Nancy Miller- Rich as Board Chair

Read More

Frances Benson 2/16/22 Frances Benson 2/16/22

eFFECTOR Therapeutics appoints Kristen Harrington-Smith to Board of Directors

Read More